S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
New AI Stock Payouts (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside

Avanos Medical (AVNS) Stock Forecast, Price & News

$20.34
+0.11 (+0.54%)
(As of 09/25/2023 ET)
Compare
Today's Range
$20.06
$20.53
50-Day Range
$19.93
$26.31
52-Week Range
$19.32
$31.99
Volume
259,786 shs
Average Volume
273,694 shs
Market Capitalization
$953.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Avanos Medical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
52.4% Upside
$31.00 Price Target
Short Interest
Healthy
1.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.61mentions of Avanos Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
44.86%
From $1.07 to $1.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

203rd out of 963 stocks

Surgical Appliances & Supplies Industry

7th out of 19 stocks


AVNS stock logo

About Avanos Medical (NYSE:AVNS) Stock

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy and OrthogenRx's knee osteoarthritis pain relief injection products. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS Price History

AVNS Stock News Headlines

New Cash Law Will Be Disaster for Savers
New law has expert warning seniors and retirees to beware. There's a darker truth behind this financial bombshell...
JMP Securities Remains a Hold on Avanos Medical (AVNS)
Q2 2023 Avanos Medical Inc Earnings Call
New Cash Law Will Be Disaster for Savers
New law has expert warning seniors and retirees to beware. There's a darker truth behind this financial bombshell...
AVNS vs. EW: Which Stock Is the Better Value Option?
Avanos Medical (AVNS) Gets a Hold from JMP Securities
JMP Securities Keeps Their Hold Rating on Avanos Medical (AVNS)
Avanos Medical Divests Respiratory Health Business To SunMed
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Company Calendar

Last Earnings
8/09/2023
Today
9/25/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
4,044
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+52.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$50.50 million
Pretax Margin
5.74%

Debt

Sales & Book Value

Annual Sales
$820 million
Cash Flow
$2.72 per share
Book Value
$27.77 per share

Miscellaneous

Free Float
45,514,000
Market Cap
$952.40 million
Optionable
Optionable
Beta
0.90
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Joseph F. Woody (Age 57)
    CEO & Director
    Comp: $2.37M
  • Mr. Michael C. Greiner (Age 50)
    Sr. VP, CFO & Chief Transformation Officer
    Comp: $940.45k
  • Ms. Mojirade James (Age 56)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $759.53k
  • Mr. Kerr W. Holbrook (Age 56)
    Sr. VP, GM of Chronic Care & Chief Commercial Officer
    Comp: $716.87k
  • Mr. John Joseph Hurley
    Principal Accounting Officer & Controller
  • Mr. David Crawford
    VP of FP&A and Investor Relations and Treasurer
  • Ms. Michelle Scharfenberg
    Sr. VP and Chief Ethics & Compliance Officer
  • Mr. Scott Galovan
    VP of Strategy & Corp. Devel.
  • John W. Cato
    VP of HR
  • Mr. Lee Burnes
    Sr. VP of Global R&D, Clinical and Medical Affairs













AVNS Stock - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month target prices for Avanos Medical's stock. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they predict the company's share price to reach $31.00 in the next year. This suggests a possible upside of 52.6% from the stock's current price.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2023?

Avanos Medical's stock was trading at $27.06 at the beginning of 2023. Since then, AVNS shares have decreased by 24.9% and is now trading at $20.32.
View the best growth stocks for 2023 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 805,800 shares, an increase of 6.8% from the July 31st total of 754,800 shares. Based on an average daily volume of 255,400 shares, the short-interest ratio is currently 3.2 days. Currently, 1.8% of the company's shares are sold short.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) issued its earnings results on Wednesday, August, 9th. The company reported $0.24 earnings per share for the quarter, missing analysts' consensus estimates of $0.34 by $0.10. The firm had revenue of $169.40 million for the quarter, compared to analyst estimates of $186.30 million. Avanos Medical had a negative net margin of 4.61% and a positive trailing twelve-month return on equity of 5.49%. The company's quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter last year, the business earned $0.41 EPS.

What ETF holds Avanos Medical's stock ?

Invesco S&P SmallCap Health Care ETF holds 119,434 shares of AVNS stock, representing 1.06% of its portfolio.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical updated its FY23 earnings guidance on Wednesday, August, 9th. The company provided EPS guidance of $1.05-$1.15 for the period, compared to the consensus earnings per share estimate of $1.52.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.64%), Dimensional Fund Advisors LP (6.68%), RGM Capital LLC (5.92%), Paradice Investment Management LLC (4.81%), State Street Corp (4.37%) and Westwood Holdings Group Inc. (3.67%).
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $20.32.

How much money does Avanos Medical make?

Avanos Medical (NYSE:AVNS) has a market capitalization of $952.40 million and generates $820 million in revenue each year. The company earns $50.50 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Avanos Medical have?

The company employs 4,044 workers across the globe.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.

This page (NYSE:AVNS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -